vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Cisco (CSCO). Click either name above to swap in a different company.

Cisco is the larger business by last-quarter revenue ($15.3B vs $11.5B, roughly 1.3× Bristol Myers Squibb). Bristol Myers Squibb runs the higher net margin — 23.3% vs 20.7%, a 2.6% gap on every dollar of revenue. On growth, Bristol Myers Squibb posted the faster year-over-year revenue change (11.0% vs 9.7%). Over the past eight quarters, Cisco's revenue compounded faster (9.9% CAGR vs -3.0%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

Cisco Systems, Inc. is an American multinational digital communications technology conglomerate corporation headquartered in San Jose, California. Cisco develops, manufactures, and sells networking hardware, software, telecommunications equipment and other high-technology services and products.

BMY vs CSCO — Head-to-Head

Bigger by revenue
CSCO
CSCO
1.3× larger
CSCO
$15.3B
$11.5B
BMY
Growing faster (revenue YoY)
BMY
BMY
+1.3% gap
BMY
11.0%
9.7%
CSCO
Higher net margin
BMY
BMY
2.6% more per $
BMY
23.3%
20.7%
CSCO
Faster 2-yr revenue CAGR
CSCO
CSCO
Annualised
CSCO
9.9%
-3.0%
BMY

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BMY
BMY
CSCO
CSCO
Revenue
$11.5B
$15.3B
Net Profit
$2.7B
$3.2B
Gross Margin
65.0%
Operating Margin
24.6%
Net Margin
23.3%
20.7%
Revenue YoY
11.0%
9.7%
Net Profit YoY
8.8%
30.8%
EPS (diluted)
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
CSCO
CSCO
Q1 26
$11.5B
$15.3B
Q4 25
$12.5B
$14.9B
Q3 25
$12.2B
$14.7B
Q2 25
$12.3B
$14.1B
Q1 25
$11.2B
$14.0B
Q4 24
$12.3B
$13.8B
Q3 24
$11.9B
$13.6B
Q2 24
$12.2B
$12.7B
Net Profit
BMY
BMY
CSCO
CSCO
Q1 26
$2.7B
$3.2B
Q4 25
$1.1B
$2.9B
Q3 25
$2.2B
$2.5B
Q2 25
$1.3B
$2.5B
Q1 25
$2.5B
$2.4B
Q4 24
$72.0M
$2.7B
Q3 24
$1.2B
$2.2B
Q2 24
$1.7B
$1.9B
Gross Margin
BMY
BMY
CSCO
CSCO
Q1 26
65.0%
Q4 25
67.2%
65.5%
Q3 25
71.9%
63.2%
Q2 25
72.5%
65.6%
Q1 25
72.9%
65.1%
Q4 24
61.0%
65.9%
Q3 24
75.1%
64.4%
Q2 24
73.2%
65.1%
Operating Margin
BMY
BMY
CSCO
CSCO
Q1 26
24.6%
Q4 25
11.8%
22.6%
Q3 25
25.5%
21.0%
Q2 25
14.5%
22.6%
Q1 25
26.5%
22.3%
Q4 24
1.4%
17.0%
Q3 24
14.1%
19.2%
Q2 24
10.5%
17.2%
Net Margin
BMY
BMY
CSCO
CSCO
Q1 26
23.3%
20.7%
Q4 25
8.7%
19.2%
Q3 25
18.0%
17.4%
Q2 25
10.7%
17.6%
Q1 25
21.9%
17.4%
Q4 24
0.6%
19.6%
Q3 24
10.2%
15.8%
Q2 24
13.8%
14.8%
EPS (diluted)
BMY
BMY
CSCO
CSCO
Q1 26
$0.80
Q4 25
$0.54
$0.72
Q3 25
$1.08
$0.64
Q2 25
$0.64
$0.62
Q1 25
$1.20
$0.61
Q4 24
$0.05
$0.68
Q3 24
$0.60
$0.54
Q2 24
$0.83
$0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
CSCO
CSCO
Cash + ST InvestmentsLiquidity on hand
$9.6B
$15.8B
Total DebtLower is stronger
$-42.2B
$24.6B
Stockholders' EquityBook value
$47.7B
Total Assets
$123.4B
Debt / EquityLower = less leverage
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
CSCO
CSCO
Q1 26
$9.6B
$15.8B
Q4 25
$10.2B
$15.7B
Q3 25
$15.7B
$16.1B
Q2 25
$12.6B
$15.6B
Q1 25
$10.9B
$16.9B
Q4 24
$10.3B
$18.7B
Q3 24
$7.9B
$17.9B
Q2 24
$6.3B
$18.8B
Total Debt
BMY
BMY
CSCO
CSCO
Q1 26
$-42.2B
$24.6B
Q4 25
$44.8B
$24.6B
Q3 25
$48.7B
$24.6B
Q2 25
$48.9B
$25.1B
Q1 25
$49.5B
$20.1B
Q4 24
$49.4B
$20.1B
Q3 24
$49.5B
$20.1B
Q2 24
$52.0B
$20.1B
Stockholders' Equity
BMY
BMY
CSCO
CSCO
Q1 26
$47.7B
Q4 25
$18.5B
$46.9B
Q3 25
$18.6B
$46.8B
Q2 25
$17.4B
$45.9B
Q1 25
$17.4B
$45.5B
Q4 24
$16.3B
$45.3B
Q3 24
$17.1B
$45.5B
Q2 24
$17.0B
$45.8B
Total Assets
BMY
BMY
CSCO
CSCO
Q1 26
$123.4B
Q4 25
$90.0B
$121.1B
Q3 25
$96.9B
$122.3B
Q2 25
$94.7B
$119.8B
Q1 25
$92.4B
$121.4B
Q4 24
$92.6B
$123.3B
Q3 24
$93.7B
$124.4B
Q2 24
$94.6B
$123.0B
Debt / Equity
BMY
BMY
CSCO
CSCO
Q1 26
0.52×
Q4 25
2.43×
0.53×
Q3 25
2.63×
0.53×
Q2 25
2.81×
0.55×
Q1 25
2.85×
0.44×
Q4 24
3.03×
0.44×
Q3 24
2.89×
0.44×
Q2 24
3.05×
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
CSCO
CSCO
Operating Cash FlowLast quarter
$1.8B
Free Cash FlowOCF − Capex
$1.5B
FCF MarginFCF / Revenue
10.0%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
0.57×
TTM Free Cash FlowTrailing 4 quarters
$12.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
CSCO
CSCO
Q1 26
$1.8B
Q4 25
$2.0B
$3.2B
Q3 25
$6.3B
$4.2B
Q2 25
$3.9B
$4.1B
Q1 25
$2.0B
$2.2B
Q4 24
$4.4B
$3.7B
Q3 24
$5.6B
$3.7B
Q2 24
$2.3B
$4.0B
Free Cash Flow
BMY
BMY
CSCO
CSCO
Q1 26
$1.5B
Q4 25
$1.6B
$2.9B
Q3 25
$6.0B
$4.0B
Q2 25
$3.6B
$3.8B
Q1 25
$1.7B
$2.0B
Q4 24
$4.1B
$3.4B
Q3 24
$5.3B
$3.5B
Q2 24
$2.1B
$3.8B
FCF Margin
BMY
BMY
CSCO
CSCO
Q1 26
10.0%
Q4 25
12.8%
19.4%
Q3 25
49.0%
27.4%
Q2 25
29.0%
26.8%
Q1 25
15.1%
14.5%
Q4 24
32.9%
24.9%
Q3 24
44.3%
25.9%
Q2 24
16.9%
29.9%
Capex Intensity
BMY
BMY
CSCO
CSCO
Q1 26
1.8%
Q4 25
3.0%
2.2%
Q3 25
2.6%
1.5%
Q2 25
2.9%
1.8%
Q1 25
2.3%
1.5%
Q4 24
3.1%
1.6%
Q3 24
2.7%
1.5%
Q2 24
2.1%
1.3%
Cash Conversion
BMY
BMY
CSCO
CSCO
Q1 26
0.57×
Q4 25
1.82×
1.12×
Q3 25
2.87×
1.66×
Q2 25
2.99×
1.63×
Q1 25
0.80×
0.92×
Q4 24
61.65×
1.35×
Q3 24
4.62×
1.73×
Q2 24
1.38×
2.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BMY
BMY

Segment breakdown not available.

CSCO
CSCO

Networking$8.3B54%
Services$3.7B24%
Security$2.0B13%
Collaboration$1.1B7%
Observability$277.0M2%

Related Comparisons